Hwang Angela 4

4 · PFIZER INC · Filed Feb 25, 2022

Form 4

Period: 2022-02-23

Group President

Transactions

Exercise/Conversion
Common Stock
2022-02-23$27.34/sh+21,359$583,955→ 21,359 total
Tax Payment
Common Stock
2022-02-23$46.87/sh−4,110$192,636→ 17,249 total
Tax Payment
Common Stock
2022-02-23$51.28/sh−10,572$542,132→ 6,677 total
Exercise/Conversion
Stock Appreciation Rights
2022-02-23−21,359→ 0 total
Exercise: $27.34From: 2022-02-23Exp: 2022-02-23→ Common Stock (21,359 underlying)
Award
Stock Appreciation Rights
2022-02-24+95,095→ 95,095 total
Exercise: $45.96From: 2027-02-24Exp: 2027-02-24→ Common Stock (95,095 underlying)
Award
Stock Appreciation Rights
2022-02-24+83,637→ 83,637 total
Exercise: $45.96From: 2029-02-24Exp: 2029-02-24→ Common Stock (83,637 underlying)

Holdings

Footnotes (7)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F4]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F5]The reporting person disclaims beneficial ownership of the shares held by spouse.
[F6]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F7]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Documents

1 file